Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate glad. * Informed of, willing, and able to comply with, the requirements of the investigational study and have signed a written informed consent in accordance with institutional regulatory guidelines. * Subjects defined as being at high risk for disease relapse based on the following criteria: PSA \> 10 ng/ml, and any one of the following: Gleason \> 7 or T stage \> T2b. * Patients must have elected to and are a candidate to undergo a radical prostatectomy. * Males greater than 18 years of age and less than or equal to 75 years of age (physiologic) any racial/ethnic group. * Free of significant abnormal findings as determined by screening history, physical exam, vital signs (blood pressure, heart rate, respiration rate, and temperature), and urinalysis. * Performance status: ECOG \< 2. * Life expectancy of at least 5 years. * Absolute granulocyte count \> 1,500/mm3. * Platelet count \> 100,000. * Hemoglobin \> 9.0 g/dL. * Serum calcium \< 12.0 mg/dL Adequate hepatic function as evidenced by ALT and AST values within normal range. Adequate organ function as defined by the following criteria: Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase \[SGOT\]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase \[SGPT\]) \< 2.5 x local laboratory upper limit of normal (ULN), or AST and ALT \< 5 x ULN if liver function abnormalities are due to underlying malignancy. * Creatinine \< 1.5 ULN. Exclusion Criteria: * Patients who have stage T2a or less prostate cancer, Gleason \< 6, PSA \<10-ng/mL. * Prior hormonal, surgical, radiopharmaceutical or radiation therapy, cryotherapy, biological response modifiers, or systematic chemotherapy to treat prostatic carcinoma. * Surgery within four weeks of study entry. * Evidence of regional and/or distant metastases. * Use of an investigational drug within 30 days prior to study entry. * NCI CTCAE Version 3.0 grade 3 hemorrhage within 4 weeks of starting the study treatment. * Any of the following thing the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism. * Ongoing cardiac dysrhythmias of NCI CTCAE Version 3.0 grade \> 2. * Prolonged QTc interval on baseline EKG. * Uncontrolled Hypertension (\>150/100 mm Hg despite optimal medical therapy). * Patients receiving CYP3A4 inducers or inhibitors; patients should not take grapefruit juice or St. John's Wort while on the study * Known active infection.